Latest Deals :)

During this recession there has been series of Merger, acquisition and licensing happening in the field of cancer therapy not only in United states, Europe but also in countries like North Korea who are making their presence felt in the global market, companies like PharmAbcine are into monoclonal antibody production and have in recent past raised money worth $6 Million for their research, At the other end there are some companies such as Anthera which are going for IPO worth $70 Million.....the recent trend which has been observed is that companies are going for cost effective M&A and licensing deals and there is no severe recession in number of deal activity in pharma..What is your say?